December 03, 2012
New evidence report added! Visit the AHRQ Evidence Reports page for a listing of reports produced under AHRQ's Evidence-based Practice Program and Effective Health Care Program.
- Save the Date! G-I-N North America is co-sponsoring with the Section on Evidence Based Health Care (SEBHC) of The New York Academy of Medicine a two-day conference on "Evidence-Based Guidelines Affecting Policy, Practice and Stakeholders (E-GAPPS)." The conference will be held December 10-11, 2012 in New York City. Registration is open and conference information is available at http://www.nyam.org/egapps2012 .
- The Guidelines International Network North America (G-I-N NA) continues to sponsor a monthly webinar series on topics of interest to the North American guideline community. Information on upcoming webinars, as well as audio files and slides from past webinars, is available on the G-I-N Web site .
U.S. Food and Drug Administration (FDA) Advisory
- December 4, 2012: Ondansetron (Zofran) 32 mg, Single Intravenous (IV) Dose : FDA is notifying health care professionals that the 32 mg, single intravenous (IV) dose of the anti-nausea drug Zofran (ondansetron hydrochloride) will no longer be marketed because of the potential for serious cardiac risks. FDA anticipates these products will be removed from the market through early 2013.